CD8A and acute myeloid leukemia: HLA-A*0201-restricted WT1-specific donor-derived CD8+ cytotoxic T-cells (CTLs) for treating high-risk or relapses of 11 patients with leukemia, including those with AML, was reported early by Chapuis et al.